Plasma N-terminal prosomatostatin and risk of incident cardiovascular disease and all-cause mortality in a prospective observational cohort: the PREVEND study, Clin. Chem, vol.63, pp.278-287, 2017. ,
Predicting progression from normal cognition to mild cognitive impairment for individuals at 5 years, Brain, vol.141, pp.877-887, 2018. ,
Regional and sub-regional differences in hippocampal GABAergic neuronal vulnerability in the TgCRND8 mouse model of Alzheimer's disease. Front, Aging Neurosci, vol.7, p.30, 2015. ,
Evaluation of CSF-tau and CSF-A?42 as diagnostic markers for Alzheimer disease in clinical practice, Arch. Neurol, vol.58, pp.373-379, 2001. ,
Neuropeptide Y in the cerebral cortex and the caudate-putamen nuclei: ultrastructural basis for interactions with GABAergic and non-GABAergic neurons, J. Neurosci, vol.9, pp.4333-4354, 1989. ,
Cerebrospinal fluid somatostatin and neuropeptide Y. Concentrations in aging and in dementia of the Alzheimer type with and without extrapyramidal signs, Arch. Neurol, vol.45, pp.269-274, 1988. ,
Clinical and biomarker changes in dominantly inherited Alzheimer's disease, N. Engl. J. Med, vol.367, pp.795-804, 2012. ,
Neuropeptides in learning and memory, Neuropeptides, vol.47, pp.439-450, 2013. ,
Somatostatin immunoreactive neurons in the human hippocampus and cortex shown by immunogold/silver intensification on vibratome sections: coexistence with neuropeptide Y neurons and effects in Alzheimer-type dementia, J. Comp. Neurol, vol.260, pp.201-223, 1987. ,
Automatic segmentation of the hippocampus and the amygdala driven by hybrid constraints: method and validation, Neuroimage, vol.46, pp.749-761, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-00805390
Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose, Arch. Gen. Psychiatry, vol.56, pp.1135-1140, 1999. ,
Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa, Nature, vol.288, pp.279-280, 1980. ,
Association of neuropeptide Y gene rs16147 polymorphism with cardiovascular risk factors, adipokines, and metabolic syndrome in patients with obesity, J. Nutrigenet. Nutrigenomics, vol.9, pp.213-221, 2016. ,
Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias, J. Neurol. Neurosurg. Psychiatry, vol.82, pp.240-246, 2011. ,
Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update, Biomark. Med, vol.6, pp.419-430, 2012. ,
DO 80 Epreuve de Dénomination Orale d'images, 1997. ,
Neuropeptide alterations in the hippocampal formation and cortex of transgenic mice overexpressing ?-amyloid precursor protein (APP) with the Swedish double mutation (APP23), Neurobiol. Dis, vol.14, pp.579-594, 2003. ,
Neuropeptides in hippocampus and cortex in transgenic mice overexpressing V717F ?-amyloid precursor protein-initial observations, Neuroscience, vol.100, pp.259-286, 2000. ,
Neuropeptide Y (NPY) as a therapeutic target for neurodegenerative diseases, Neurobiol. Dis, vol.95, pp.210-224, 2016. ,
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria, Lancet Neurol, vol.13, issue.14, pp.70090-70090, 2014. ,
Vascular risk factors, cognitive decline, and dementia. Vasc. Health Risk Manag, vol.4, pp.363-381, 2008. ,
Neuropeptides in cerebrospinal fluid of patients with Alzheimer's disease and dementia with frontotemporal lobe degeneration, Dementia, vol.4, pp.167-171, 1993. ,
Preclinical Alzheimer's disease: a systematic review of the cohorts underlying the concept, Alzheimers Dement, vol.13, pp.454-467, 2017. ,
Somatostatin, Alzheimer's disease and cognition: an old story coming of age?, Prog. Neurobiol, vol.89, pp.153-161, 2009. ,
Somatostatin and dementia in Parkinson's disease, Brain Res, vol.278, issue.83, pp.90277-90286, 1983. ,
Age-related gene expression in the frontal cortex suggests synaptic function changes in specific inhibitory neuron subtypes, Front. Aging Neurosci, vol.9, p.162, 2017. ,
Impact of the 2008-2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM study, J. Alzheimers Dis, vol.34, pp.297-305, 2013. ,
Widespread deficits in somatostatin but not neuropeptide Y concentrations in Alzheimer's disease cerebral cortex, Neurosci. Lett, vol.155, issue.93, p.90686, 1993. ,
Expression of Somatostatin, cortistatin and their receptors, as well as dopamine receptors, but not of neprilysin, are reduced in the temporal lobe of Alzheimer's disease patients, J. Alzheimers Dis, vol.20, pp.465-475, 2010. ,
Subpopulations of somatostatin 28-immunoreactive neurons display different vulnerability in senile dementia of the Alzheimer type, Brain Res, vol.490, pp.1-13, 1989. ,
Screening for dementia by memory testing, Neurology, vol.38, pp.900-903, 1988. ,
Memory impairment on free and cued selective reminding predicts dementia, Neurology, vol.54, pp.827-832, 2000. ,
Loss of somatostatin-like immunoreactivity in the frontal cortex of Alzheimer patients carrying the apolipoprotein epsilon 4 allele, Neurosci. Lett, vol.255, pp.21-24, 1998. ,
Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers, Alzheimers Dement, vol.13, pp.903-912, 2017. ,
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study, Lancet Neurol, vol.5, pp.228-234, 2006. ,
N-terminal prosomatostatin as a risk marker for cardiovascular disease and diabetes in a general population, J. Clin. Endocrinol. Metab, vol.101, pp.2016-1736, 2016. ,
Cerebrospinal fluid neuropeptides in Alzheimer's disease and vascular dementia, Biol. Psychiatry, vol.38, pp.210-216, 1995. ,
, , 2017.
, N-terminal prosomatostatin and risk of vascular dementia, Cerebrovasc. Dis, vol.44, pp.259-265
Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function, JAMA, vol.185, pp.914-919, 1963. ,
Polymorphism in neuropeptide Y influences CSF cholesterol levels but is no major risk factor of Alzheimer's disease, J. Neural Transm, vol.113, pp.231-238, 2006. ,
Cortical somatostatin, neuropeptide Y, and NADPH diaphorase neurons: normal anatomy and alterations in Alzheimer's disease, Ann. Neurol, vol.23, pp.105-114, 1988. ,
Assessment of older people: self-maintaining and instrumental activities of daily living, Gerontologist, vol.9, pp.179-186, 1969. ,
A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles, Alzheimers Res. Ther, vol.6, p.38, 2014. ,
Management of neurogenic orthostatic hypotension: an update, Lancet Neurol, vol.7, pp.70088-70095, 2008. ,
Neuropeptide Y receptor binding sites in human brain. Possible alteration in Alzheimer's disease, Brain Res, vol.519, pp.228-235, 1990. ,
Somatostatinergic systems: an update on brain functions in normal and pathological aging, Front. Endocrinol, vol.3, p.154, 2012. ,
Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type, J. Neural Transm. Park Dis. Dement. Sect, vol.4, pp.191-205, 1992. ,
FK962 and donepezil act synergistically to improve cognition in rats: potential as an add-on therapy for Alzheimer's disease, Pharmacol. Biochem. Behav, vol.98, pp.76-80, 2011. ,
Blood pressure from mid-to late life and risk of incident dementia, Neurology, vol.89, pp.2447-2454, 2017. ,
CATI: a large distributed infrastructure for the neuroimaging of cohorts, Neuroinformatics, vol.14, pp.253-264, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01303094
Network abnormalities and interneuron dysfunction in Alzheimer disease, Nat. Rev. Neurosci, vol.17, pp.777-792, 2016. ,
Mild cognitive impairment as a diagnostic entity, J. Intern. Med, vol.256, pp.183-194, 2004. ,
Exploring anterograde memory: a volumetric MRI study in patients with mild cognitive impairment, Alzheimers Res. Ther, vol.8, p.26, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01382516
Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's disease, J. Neurol. Neurosurg. Psychiatry, vol.77, pp.714-718, 2006. ,
Early neuropathology of somatostatin/NPY GABAergic cells in the hippocampus of a PS1xAPP transgenic model of Alzheimer's disease, Neurobiol. Aging, vol.27, pp.1658-1672, 2006. ,
The space where aging acts: focus on the GABAergic synapse, Aging Cell, vol.16, pp.634-643, 2017. ,
Somatostatin regulates brain amyloid ? peptide A?42 through modulation of proteolytic degradation, Nat. Med, vol.11, pp.434-439, 2005. ,
Interneurons, tau and amyloid-? in the piriform cortex in Alzheimer's disease, Brain Struct. Funct, vol.220, 2011. ,
Interneurons in the human olfactory system in Alzheimer's disease, Exp. Neurol, vol.276, pp.13-21, 2016. ,
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, vol.7, pp.280-292, 2011. ,
Interneuron loss reduces dendritic inhibition and GABA release in hippocampus of aged rats, Neurobiol. Aging, vol.33, 2012. ,
Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age, JAMA Neurol, vol.72, pp.1029-1042, 2015. ,
Alzheimer's disease: low cerebral somatostatin levels correlate with impaired cognitive function and cortical metabolism, Neurology, vol.37, pp.161-165, 1987. ,
Manuel d'application de la Batterie Factorielle P.M.A (Primary Mental Activities), 1964. ,
Trail making test A and B: normative data stratified by age and education, Arch. Clin. Neuropsychol, vol.19, pp.39-47, 2004. ,
Somatostatin modulates insulin-degrading-enzyme metabolism: implications for the regulation of microglia activity in AD, PLoS One, vol.7, p.34376, 2012. ,
NADPH-diaphorase-positive cell populations in the human amygdala and temporal cortex: neuroanatomy, peptidergic characteristics and aspects of aging and Alzheimer's disease, Acta Neuropathol, vol.83, pp.636-646, 1992. ,
Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies, Clin. Chem. Lab. Med, vol.44, pp.1472-1480, 2006. ,
A new neuronal target for ?-amyloid peptide in the rat hippocampus, Neurobiol. Aging, vol.33, pp.1-1126, 1126. ,
Decreased rhythmic GABAergic septal activity and memoryassociated theta oscillations after hippocampal amyloid-? pathology in the rat, J. Neurosci, vol.30, pp.10991-11003, 2010. ,
Somatostatin binds to the human amyloid ? peptide and favors the formation of distinct oligomers, Elife, vol.6, p.28401, 2017. ,
Effects of insulin and octreotide on memory and growth hormone in Alzheimer's disease, J. Alzheimers Dis, vol.18, pp.595-602, 2009. ,
Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2, J. Neurosci, vol.28, pp.1537-1545, 2008. ,
Geriatric depression scale, Psychopharmacol. Bull, vol.24, pp.709-711, 1988. ,
, Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, Copyright, 2018. ,